These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30876800)

  • 41. Increased CCL18 expression in patients with cutaneous T-cell lymphoma: association with disease severity and prognosis.
    Miyagaki T; Sugaya M; Suga H; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e60-7. PubMed ID: 22404649
    [TBL] [Abstract][Full Text] [Related]  

  • 42. NLRP3 Regulates IL-4 Expression in TOX
    Huanosta-Murillo E; Alcántara-Hernández M; Hernández-Rico B; Victoria-Acosta G; Miranda-Cruz P; Domínguez-Gómez MA; Jurado-Santacruz F; Patiño-López G; Pérez-Koldenkova V; Palma-Guzmán A; Licona-Limón P; Fuentes-Pananá EM; Lemini-López A; Bonifaz LC
    Front Immunol; 2021; 12():668369. PubMed ID: 34220814
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cobomarsen, an oligonucleotide inhibitor of miR-155, co-ordinately regulates multiple survival pathways to reduce cellular proliferation and survival in cutaneous T-cell lymphoma.
    Seto AG; Beatty X; Lynch JM; Hermreck M; Tetzlaff M; Duvic M; Jackson AL
    Br J Haematol; 2018 Nov; 183(3):428-444. PubMed ID: 30125933
    [TBL] [Abstract][Full Text] [Related]  

  • 44. New Genetic Markers of Skin T-Cell Lymphoma Treatment.
    Vašků V; Fialová P; Vašků A
    Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540417
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior.
    Berti E; Tomasini D; Vermeer MH; Meijer CJ; Alessi E; Willemze R
    Am J Pathol; 1999 Aug; 155(2):483-92. PubMed ID: 10433941
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systemic therapy of cutaneous T-cell lymphoma (CTCL).
    Alpdogan O; Kartan S; Johnson W; Sokol K; Porcu P
    Chin Clin Oncol; 2019 Feb; 8(1):10. PubMed ID: 30818958
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination of retinoid and histone deacetylase inhibitor produced an anti-tumor effect in cutaneous T-cell lymphoma by restoring tumor suppressor gene, retinoic acid receptorβ2, via histone acetylation.
    Kato Y; Egusa C; Maeda T; Tsuboi R
    J Dermatol Sci; 2016 Jan; 81(1):17-25. PubMed ID: 26596218
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update.
    Ramelyte E; Dummer R; Guenova E
    Expert Opin Investig Drugs; 2019 Sep; 28(9):799-809. PubMed ID: 31398295
    [No Abstract]   [Full Text] [Related]  

  • 49. Reversible resistance to apoptosis in cutaneous T cell lymphoma.
    Meech SJ; Edelson R; Walsh P; Norris DA; Duke RC
    Ann N Y Acad Sci; 2001 Sep; 941():46-58. PubMed ID: 11594582
    [TBL] [Abstract][Full Text] [Related]  

  • 50. miR-155 expression in Primary Cutaneous T-Cell Lymphomas (CTCL).
    Fava P; Bergallo M; Astrua C; Brizio M; Galliano I; Montanari P; Daprà V; Novelli M; Savoia P; Quaglino P; Fierro MT
    J Eur Acad Dermatol Venereol; 2017 Jan; 31(1):e27-e29. PubMed ID: 26935979
    [No Abstract]   [Full Text] [Related]  

  • 51. Angiogenin levels are increased in lesional skin and sera in patients with erythrodermic cutaneous T cell lymphoma.
    Miyagaki T; Sugaya M; Suga H; Akamata K; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
    Arch Dermatol Res; 2012 Jul; 304(5):401-6. PubMed ID: 22526325
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clonal disease in extracutaneous compartments in cutaneous T-cell lymphomas. A comparative study between cutaneous T-cell lymphomas and pseudo lymphomas.
    Dommann SN; Dommann-Scherrer CC; Dours-Zimmermann MT; Zimmermann DR; Kural-Serbes B; Burg G
    Arch Dermatol Res; 1996 Apr; 288(4):163-7. PubMed ID: 8967786
    [TBL] [Abstract][Full Text] [Related]  

  • 53. NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
    Kießling MK; Nicolay JP; Schlör T; Klemke CD; Süss D; Krammer PH; Gülow K
    Oncotarget; 2017 Jul; 8(28):45687-45697. PubMed ID: 28537899
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel xenograft model of cutaneous T-cell lymphoma.
    Krejsgaard T; Kopp K; Ralfkiaer E; Willumsgaard AE; Eriksen KW; Labuda T; Rasmussen S; Mathiesen AM; Geisler C; Lauenborg B; Becker JC; Zhang Q; Wasik MA; Odum N; Woetmann A
    Exp Dermatol; 2010 Dec; 19(12):1096-102. PubMed ID: 20629733
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Future directions for pentostatin (Nipent) usage in dermatology.
    Heald P
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):3-8. PubMed ID: 10877044
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic and epigenetic insights into cutaneous T-cell lymphoma.
    Tensen CP; Quint KD; Vermeer MH
    Blood; 2022 Jan; 139(1):15-33. PubMed ID: 34570882
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Functional Depletion of HSP72 by siRNA and Quercetin Enhances Vorinostat-Induced Apoptosis in an HSP72-Overexpressing Cutaneous T-Cell Lymphoma Cell Line, Hut78.
    Fujii K; Idogawa M; Suzuki N; Iwatsuki K; Kanekura T
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681913
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
    Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
    Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
    Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
    Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells.
    Qin JZ; Zhang CL; Kamarashev J; Dummer R; Burg G; Döbbeling U
    Blood; 2001 Nov; 98(9):2778-83. PubMed ID: 11675351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.